NCT06927232
AZA+Lus VS AZA Monotherapy in HR-MDS
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Completed without a posted recruiting period
- Study completion date changed from estimate of Jan 31, 2027 to Jan 31, 2026
- Start date changed from estimate of Apr 2025 to Apr 24, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
overall response rate
Timeframe: 3 months, 6 months
Secondary (6)
complete response rate
rate of transfusion independence
adverse event rate
relapse rate
progress-free survival
Show 1 moreShow less
overall survival
Arms and interventions
Azacitidine+LuspaterceptExperimental
AzacitidineActive comparator
Drugs: Azacitidine (AZA), Luspatercept
Sites
1 site in 1 country
- Peking union medical college hospitalBeijing, N/A 不适用, China